Ceva Santé Animale & IDT Biologika GmbH have reached an agreement for Ceva to acquire IDT’s veterinary biopharmaceutical portfolio and R&D activities.
Strong synergies exist between the two companies’ swine and poultry vaccine ranges and Ceva’s global geographic footprint will allow rapid expansion of the sales of the current IDT product range to the rest of the world. With the global shift towards preventative medicines, both companies have a long history and proven track record of developing vaccines. Ceva plans to invest significantly in the development of a new Global Swine Innovation Centre at IDT’s existing Dessau site as well as at IDT Research in Riems, Germany. The centre will strengthen Ceva’s biological R&D capabilities, bringing together two highly skilled research teams and innovative pipelines with strong growth potential. IDT has significant expertise in a number of other areas, including autogenous vaccines and oral vaccination for the control of endemic disease in wildlife and free roaming animals, adding important new technology to Ceva’s growing public health business.
Ceva Santé Animale -beneficiary in the PIGSs project- is a French multinational veterinary pharmaceutical company created in 1999. Chaired by Dr. Marc Prikazsky, Ceva specializes in the research, development, production and marketing of pharmaceutical products and vaccines for livestock (ruminants, swine, poultry) and companion animals. Ceva is present in 110 countries and employs over 5700 people worldwide. Since 2007, its management and employees have been the majority shareholders in Ceva Santé Animale, which Chairman and CEO is Dr. Marc Prikazsky.